NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Blair William & Co. IL

Blair William & Co. IL trimmed its holdings in NeoGenomics, Inc. (NASDAQ:NEO) by 13.5% during the second quarter, Holdings Channel reports. The institutional investor owned 409,182 shares of the medical research company’s stock after selling 63,688 shares during the period. Blair William & Co. IL’s holdings in NeoGenomics were worth $5,675,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Arizona State Retirement System increased its holdings in shares of NeoGenomics by 2.0% during the 2nd quarter. Arizona State Retirement System now owns 35,739 shares of the medical research company’s stock worth $496,000 after buying an additional 708 shares during the last quarter. Crossmark Global Holdings Inc. increased its stake in NeoGenomics by 2.9% during the second quarter. Crossmark Global Holdings Inc. now owns 29,494 shares of the medical research company’s stock worth $409,000 after acquiring an additional 842 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in shares of NeoGenomics by 22.0% in the 4th quarter. Quadrant Capital Group LLC now owns 4,900 shares of the medical research company’s stock worth $79,000 after purchasing an additional 883 shares during the period. Banque Cantonale Vaudoise grew its holdings in shares of NeoGenomics by 6.6% during the 1st quarter. Banque Cantonale Vaudoise now owns 15,942 shares of the medical research company’s stock worth $251,000 after purchasing an additional 993 shares during the period. Finally, Oppenheimer Asset Management Inc. increased its position in NeoGenomics by 3.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 32,505 shares of the medical research company’s stock worth $451,000 after purchasing an additional 1,030 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Performance

NeoGenomics stock opened at $16.28 on Friday. NeoGenomics, Inc. has a 12-month low of $11.03 and a 12-month high of $21.22. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.01 and a quick ratio of 1.93. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of -24.67 and a beta of 1.19. The firm’s fifty day moving average price is $16.05 and its 200 day moving average price is $14.95.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $164.50 million for the quarter, compared to analyst estimates of $161.82 million. NeoGenomics had a negative return on equity of 2.72% and a negative net margin of 12.50%. The company’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.09) earnings per share. On average, research analysts forecast that NeoGenomics, Inc. will post -0.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on NEO shares. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a research report on Tuesday, July 30th. Stephens restated an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a report on Tuesday, July 30th. Finally, Benchmark reiterated a “buy” rating and issued a $18.00 price target on shares of NeoGenomics in a report on Tuesday, July 30th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.89.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.